FDA approves Nerlynx to reduce risk of recurrent breast cancer
Tuesday, July 18, 2017 - 14:52
in Health & Medicine
The U.S. Food and Drug Administration today approved the use of Nerlynx to treat early-stage HER2-positive breast cancer to lower remission risk.